Abbott (NYSE:ABT) today shared new clinical trial findings supporting its Aveir AR leadless atrial pacemaker system.

Minimizing atrial pacing does not prevent atrial fibrillation in patients with sinus node dysfunction, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.

Please provide your email address to receive an email when new articles are posted on . Rate-modulated pacing at 60 bpm did not reduce AF incidence vs. nonadaptive pacing at 40 bpm in patients with ...

DEAR DR. ROACH: At age 76, I was diagnosed with sinus node dysfunction last year after several episodes of what I’d call being “spaced out” (for lack of a better term). I couldn’t explain these ...

AMSTERDAM -- Reducing atrial pacing didn't help prevent atrial fibrillation (Afib, or AF) in patients with sinus node dysfunction but did increase risk of fainting, the DANPACE II trial showed. The ...

AMSTERDAM, the Netherlands—In patients with sinus node dysfunction treated with dual-chamber pacemakers, minimizing atrial pacing doesn’t lower the likelihood of developing atrial fibrillation (AF) ...

Amsterdam, Netherlands – 28 Aug 2023: Minimising atrial pacing does not prevent atrial fibrillation in patients with sinus node dysfunction, according to late breaking research presented in a Hot Line ...

NEW ORLEANS -- A leadless dual-chamber pacemaker with bidirectional wireless communication turned in very promising short-term results in patients with standard indications for dual-chamber pacing, ...

Dear Dr. Roach: At age 76, I was diagnosed with sinus node dysfunction last year after several episodes of what I’d call being “spaced out” (for lack of a better term). I couldn’t explain these ...